Search

Now showing items 1-1 of 1

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.

Huh, WK; Joura, EA; Giuliano, AR; Iversen, O-E; de Andrade, RP; Ault, KA; Bartholomew, D; Cestero, RM; Fedrizzi, EN; Hirschberg, AL;... (2017-11-11)

BACKGROUND: Primary analyses of a study in young women aged 16-26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections and disease ...